title: [Parameters of cellular and humoral immunity in patients with diabetes mellitus in the early stages of disease development; experience in treatment with the immunosuppressant azathioprine].
abstract: A total of 40 patients with type I diabetes mellitus, in whom the disease was diagnosed 1 to 12 months previously, were examined. An imbalance between the T and B cellular components of the immunity was found in the patients with the early stages of the disease, as was an elevated titer of the complement C1 component as against the reference group. The degree of the immunologic shifts was in direct correlation with the HLA A9 antigen expression, this relationship being the most marked in cases with the HLA DR3 and DR4. The incidence of these antigens expression was significantly higher in the patients with marked immunity shifts, than in those with negligible immunity changes. Therapy with an immunosuppressant azathioprine was associated with a noticeable reduction of the initially elevated cellular immunity parameters (total T and B lymphocyte counts, T helpers-inductors, DR carriers) and a trend towards a reduction of all the components and total activity of the classical route of the complement activation predominantly at the expense of the C1 and C5 components. The efficacy of this drug in therapy of new cases of insulin-dependent diabetes mellitus was confirmed, and the indisputable relationship between the efficacy of immunity suppression, that helped achieve a clinical remission, and the disease duration, was demonstrated. Monitoring of the cellular and humoral immunity parameters, of the activity of the classical route of the complement activation permitted an indirect judgement on the usefulness of immunity suppression for the correction of immunity disorders as factors contributing to the development of microvascular disturbances in insulin-dependent diabetes mellitus.
authors.forename: I I
authors.initials: II
authors.lastname: Dedov
authors.forename: I A
authors.initials: IA
authors.lastname: Abugova
authors.forename: P I
authors.initials: PI
authors.lastname: Shishko
authors.forename: M Sh
authors.initials: MSh
authors.lastname: Shamkhalova
mesh_terms: D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D003172:Complement C1 / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015234:HLA-A Antigens / Q000097:blood; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors
chemical_list: D003172:Complement C1; D015234:HLA-A Antigens; C037709:HLA-A9 antigen; D001379:Azathioprine
vernacular_title: Pokazateli kletochnogo i gumoral'nogo immuniteta u bol'nykh sakharnym diabetom na rannikh étapakh ego razvitiia; opyt lecheniia immunosupressantom azatioprinom.